Introduction
Psoriasis is a chronic disorder characterised by erythematous plaques, patches and papules which may be pruritic and classically have silver scale. Morphologically there are varying forms, with 80-90% being of the plaque variety. Other less common psoriasis forms include inverse psoriasis (involving the skin folds), erythrodermic (from chronic plaque psoriasis or acute), pustular and guttate (with 'dewdrop' lesions). 1 The peak onset of psoriasis occurs during the teenage and early adult years which means that most patients will be affected for the majority of their lives. This necessitates careful consideration as to the short-, medium-and long-term risks of psoriasis, its comorbidities and its treatments. The consequences of severe psoriasis are more than just skin deep. It may be associated with conditions such as arthritis, liver disease, cardiovascular disease and the metabolic syndrome. Severe psoriasis involves large areas of the skin's surface. Due to the chronic and very visual nature of this disease, there can be profound psychosocial consequences. 2 The autoimmune lesions of psoriasis are hyperproliferative, Psoriasis involving sensitive skin areas such as genitals, groin and face or the glabrous skin of the hands and feet is often symptomatic. Involvement of these areas is particularly likely to adversely impact on activities of daily living, personal interactions, especially those involving skin contact, and the ability to work.
The aims and frustrations of therapy
Patients want a safe, convenient therapy that will rapidly clear their disease and keep it in remission. Surveys of patient support groups have found most patients were not satisfied with the control obtained with standard therapies. Around a third felt that their medical treatment was insufficiently aggressive. To add to their frustration, patients often trial a therapy for several months before their treatment is altered because of an inadequate response. Following a switch, the mean time to treatment failure is another 3-6 months. 3 Untreated severe psoriasis tends to follow a fluctuating but persistent course. In contrast, the course of disease in mild to moderate psoriasis is generally one of relapse and remission.
Phototherapy and standard systemic drugs in severe psoriasis
Our standard therapies can control psoriasis in the majority of patients with severe psoriasis (Table 1) Phototherapy can cause erythema, pruritus and nausea. High cumulative doses increase the risk of skin cancer. 4 Cyclosporin usually works quickly to clear psoriasis (6-12 weeks) and is generally very effective in maintaining disease remission. It is thought to rebalance the T cell response away from the psoriatic diathesis.
Biological therapies appear to work in severe psoriasis irrespective of the response to standard therapies. However, there must have been an inadequate response or significant intolerance to at least three treatments before patients can use a biological therapy subsidised by the Pharmaceutical Benefits Scheme (PBS). There are no markers, other than a trial of therapy, to help us identify responders to biological therapies.
Most patients start to improve by four weeks and achieve good reductions in disease severity by 12 weeks. Infliximab is associated with the best response rates as 80% of patients achieve a 75% improvement in their psoriasis area and severity index which equates closely to disease clearance. The greatest improvements in quality of life are with infliximab followed by etanercept. 6 To date the literature on combination therapy involving biologicals is extremely limited. This area needs to be further explored to improve patient outcomes and important drug safety issues such as skin cancer.
Safety
The efficacy and safety of the biological therapies requires longterm disease-specific data. The effects associated with psoriasis and the toxicities of previous therapies are likely to influence the frequency and severity of the harm associated with long-term treatment, particularly when using an immunosuppressive drug.
The safety data from a cohort of patients treated with efalizumab continuously for longer than 2.5 years is a reassuring beginning and suggests that efficacy is well maintained. 7 However, this cohort differs significantly in their disease severity and previous treatments from those currently qualifying for therapy subsidised by the PBS. Serious adverse events with efalizumab include infections and severe arthritis. Good long-term control of the inflammation due to severe psoriasis could theoretically reduce the background risk of malignancy such as lymphoma. However, this is likely to be counterbalanced by the immunosuppressive actions of therapies for severe psoriasis. All appropriate recommendations for cancer screening should be followed.
Risk of disease rebound

Renal and cardiovascular problems
Periodontal disease
Good dental hygiene and regular dental review are important for everyone on immunosuppressive therapy. Cyclosporin carries the greatest risks for causing as well as worsening periodontal disease, including acute and chronic gingivitis and gingival hypertrophy. When taking a medication history for a patient presenting with potential sepsis, remember to ask about injectable drugs, including the biological therapies.
Infections and vaccination
Pregnancy and lactation
Effective pregnancy prevention advice and precautions need to be regularly provided and checked when women of childbearing age are taking systemic psoriasis therapies.
Should pregnancy occur, all systemic psoriasis drugs should be stopped immediately and specialist advice sought. The risk of disease rebound with efalizumab has to be balanced against the uncertain risk to the fetus. Acitretin and methotrexate have significant proven adverse effects on the fetus. The long half-life of acitretin means that a planned pregnancy must be postponed for several years after stopping treatment. Cyclosporin has been used in pregnancy when severe psoriasis has not responded to other therapies. The safety of biological therapies in pregnancy and breastfeeding is unknown.
Psoriatic arthritis
Approximately 10% of patients with psoriasis also have psoriatic arthropathy. Drugs which improve the skin may have less effect on the arthritis. 
Conclusion
Biological therapies for psoriasis are proving valuable for achieving and maintaining disease control in patients with severe psoriasis. They complement rather than replace our standard therapies. They also provide alternatives in resistant disease and greater therapeutic choice should allow better tailoring of treatment to the patient's needs. Treatment choice should take into consideration the order in which drugs are prescribed, a person's stage in life, associated comorbidities and variation in disease severity. The best use of biological therapies will be guided by the ongoing collection of data on their longterm safety.
Self-test questions
The following statements are either true or false (answers on page 27)
1. Patients with severe psoriasis may experience a flare-up of the disease when treatment with efalizumab is ceased.
2. Women taking acitretin should not plan to become pregnant until at least two years after stopping treatment. 
Further reading
Dental notes
Prepared by Michael McCullough, Chair, Therapeutics Committee, Australian Dental Association
Treatments for severe psoriasis
Dentists have become increasingly aware of the effects that systemic medications can have on the oral cavity.
Cyclosporin has long been known to be associated with gingival enlargement, and the degree of enlargement appears to be associated with both the daily dose and length of time the drug is taken. This was first observed in patients with renal transplants and these patients remain the group most commonly affected by cyclosporin-induced gingival hyperplasia. 1 However, cyclosporin and other immunomodulatory drugs are commonly used for patients with severe psoriasis. Cyclosporin-induced gingival enlargement resolves following cessation of the drug and, in some patients, it will also resolve following a reduction in drug dosage. 2 A recent study has shown that isotretinoin (a retinoid used for severe acne) has significant oral adverse effects with a decrease in salivary flow and a concomitant increase in the number of decayed, missing or filled teeth. 3 It is possible that acitretin (a retinoid used for severe psoriasis) could have a similar effect.
Acitretin is known to cause dry mouth and gingivitis. Patients taking methotrexate also have a decrease in salivary function, although this has not been studied in patients with severe psoriasis. People taking medication for severe psoriasis require very high levels of oral hygiene and regular professional cleaning to prevent or minimise deterioration of their periodontal structures. It would be advisable for these measures to start at the same time they begin their treatment for psoriasis.
